IDX Chooses bioaccess™ to Seek Licensing Data Collaboration Partners In Latin America
[Orlando, FL, February 17, 2019] — IDx Technologies Inc. has chosen bioaccess™ as its market access consultant to search, find, and select high-volume ophthalmology centers in Latin America that can be its data-licensing collaboration partners for its breakthrough autonomous artificial intelligence (AI) system that detects diseases in medical images. IDx aims to increase patient access to high-quality, affordable disease detection by enabling diagnostic assessment in primary care settings.
IDx’ first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
On April 11, 2018, IDx hit the national spotlight after receiving FDA clearance for IDx-DR, an autonomous AI system that detects diabetic retinopathy, the leading cause of blindness in the U.S. This marked the first time the FDA has ever cleared an autonomous AI diagnostic system that does not require a physician to interpret the images or results, enabling specialty level diagnostics in primary care. However, this historic clearance is only one of many milestones achieved by IDx in 2018. The company also secured a significant round of venture funding and launched IDx-DR in patient care.
At a time when the world is eager to see AI make a real-world impact amidst the hype, it is refreshing to see the technology being used to improve patients’ lives. For people with diabetes living in rural areas, like Kevin Sales, being able to be tested for diabetic retinopathy in a single office visit could be what prevents him from going blind.
IDx-DR is granted a “Breakthrough Device” designation from the FDA — a classification that offers expedited review of technologies that “provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition” (February 2018)
IDx founder and CEO Dr. Michael Abramoff awarded U.S. Patent No. 9,924,867 for systems that automatically measure cardiovascular health from the retina (March 2018)
IDx-DR earned FDA clearance, becoming the first autonomous AI system to be cleared to assess without requiring a physician to interpret the images or results (April 2018)
IDx-DR launched at the Diabetes and Endocrinology Center at University of Iowa Health Care (June 2018)
Pivotal trial study for IDx-DR FDA clearance published in Nature Digital Medicine (August 2018)
IDx closed series A funding from strategic investors, including 8VC and Optum Ventures, the venture arm of UnitedHealth Group (September 2018)
IDx signed an exclusive AI partnership agreement with Topcon, the world’s leading ophthalmic device manufacturer (October 2018)
Dr. Abramoff testified for the Federal Trade Commission on AI in healthcare (November 2018)
Dr. Abramoff awarded U.S. Patent No. 10,140,699, which covers AI systems, both medical and non-medical, that use sample training data to detect objects in images (November 2018)
IDx more than doubled its staff, growing from 23 employees to 51 in 2018 (December 2018)
IDx is expanding its reach to Latin America and has chosen bioaccess.™ as its market access consulting company to help the company find, search, and select high-volume ophthalmology centers in Latin America that can be its data-licensing collaboration partners for its breakthrough autonomous artificial intelligence (AI) system that detects diseases in medical images —specifically for glaucoma and age-related macular degeneration (AMD) and/or macular edema (DME).
About IDx Technologies Inc.
IDx (www.eyediagnosis.net) is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous AI that detects disease in medical images. IDx aims to increase patient access to high-quality, affordable disease detection by enabling diagnostic assessment in primary care settings. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx-DR is intended for use by health care providers to automatically detect more than mild diabetic retinopathy in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400, an easy-to-use and highly accurate robotic fundus camera. IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
About bioaccess.™
bioaccess™ (www.bioaccessla.com) is a Florida-based clinical research organization (CRO) and market access consulting company whose mission is to help innovative life science companies conduct clinical research and commercialize their innovations in Colombia and the rest of Latin America.
bioaccess.™ Press Contact:
Julio G. Martinez-Clark, CEO
Tel: +1 (954) 903-7210
Email: jmclark@bioaccessla.com
